Strength of Wisconsin Biohealth

Digital Health:

Where digital technology meets health solutions. Digital health is empowering patients and healthcare systems to provide personalized care, improve quality, and reduce costs. Digital health is Wisconsin’s newest and fastest growing sector.

Medical Device & Diagnostics:

The medical device and diagnostics industry continues to grow and thrive in Wisconsin, with medical device companies ranging from start-ups to corporate powerhouses choosing to call Wisconsin home.

Health Research Institutes:

Wisconsin boasts some of the nations top research institutes. Wisconsin research institutes received $407 million in NIH funding in 2015 with over 927 NIH grants being awarded.

Biotech & Biopharma:

From therapeutic and drug development to translational and integrated science, Wisconsin has it all. Accounting for one of the states’s largest economic drivers, biotech and biopharma continue to flourish in Wisconsin.

Wisconsin: A National Hub for Biomanufacturing

Top Talent. Top Resources. Top Industry.

Innovation. Right here, in Wisconsin.

Arrowhead Pharmaceuticals is back in the clinic. On Thursday, Pasadena, CA-based Arrowhead—which houses its research and development operations in Madison, WI—said regulators cleared the company to initiate a clinical study of a drug it’s developing to treat chronic hepatitis B virus.

Arrowhead (NASDAQ: ARWR) said it expects to enroll about 60 patients in the Phase 1/2 study. They’ll begin receiving the drug, ARO-HBV, by the end of March, the company said.

Arrowhead said it received approval from the New Zealand Medicines and Medical Devices Safety Authority to proceed with the trial. It is slated to take place in that country’s largest city, Auckland. Read more here.

Stratatech is moving forward with tests of a genetically engineered human skin that could heal the sores and wounds many diabetic patients get on their feet.

Madison, WI-based Stratatech, a subsidiary of U.K.-based Mallinckrodt (NYSE: MNK), said Wednesday that it had enrolled the first patient in a study of the skin tissue, called ExpressGraft-C9T1.

Stratatech said the ExpressGraft skin tissue builds on some of the same technologies the company pioneered in developing StrataGraft, its flagship skin replacement product. StrataGraft is cell-based skin tissue designed to coax the bodies of burn patients into regenerating skin. Read more here.

NorthStar Medical Radioisotopes, LLC, (NorthStar) a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has approved the RadioGenixTM System, an innovative, high tech radioisotope separation platform indicated for use in producing the widely used medical radioisotope technetium-99 (Tc-99m) from NorthStar’s non-uranium based molybdenum-99 (Mo-99).

There has been no U.S. production of Mo-99, the parent isotope of Tc-99m, for more than 25 years. The supply of Mo-99 has been subject to frequent and sometimes prolonged interruptions, disrupting and often delaying the diagnosis and treatment of patients in need of medically important diagnostic tests that require the use of this radioisotope. Furthermore, current bulk production of Mo-99 is based on enriched uranium, which poses significant environmental concerns. Read more here.

Amid predictions that this year’s flu vaccine will offer limited protection, medical researchers are renewing their focus on a universal flu vaccine.

A universal flu vaccine would offer more broad protection than today’s vaccines, which must be targeted at viral strains deemed dangerous many months before flu season begins.

The problem is that the flu virus can change fast enough to evade those vaccines.

No versatile influenza vaccine is on the market, but one of the most promising is being developed by FluGen, a spinoff from the University of Wisconsin–Madison. The Madison startup has announced a plan to evaluate its innovative influenza vaccine in a trial of 100 people later this spring. Read more here.

Imbed Biosciences, a young Fitchburg company that has developed an ultrathin film to heal wounds, is poised to launch its product this spring with the help of the latest injection of funds from investors.

A “national wound care company” will partner with Imbed and will market Microlyte Ag, said Ankit Agarwal, Imbed CEO and co-founder. The partner company’s name is not being released yet.

Microlyte Ag is a patented, ultrathin film coated with tiny silver particles that stick to the surface of the wound and kill bacteria. The U.S. Food and Drug Administration cleared it in August 2016 as a medical device, for prescription and over-the-counter use. Read more here.



Welcome home: Wisconsin is home to endless outdoor activities throughout all seasons, growing tech & health industries, and a top-tier university system making our home the 8th state in the 2016 Quality of Life list by Forbes.



When industries and instituitions converge and great minds connect, big things happen. Read about collaboration success stories that started right here in Wisconsin and learn how to start your own collaboration story.



Wisconsin boasts both a world-class university system and top-tier talent.  Madison ranks 1st for STEM college graduates. Search our career center for opportunites or find your future hire here:

2015 Wisconsin Bioscience Economic Development Report: Energizing Wisconsin's Economy


Contact our team member Kate at to learn how to get involved!

Sign Up For Our NewsletterView WI Biohealth eventsFollow Us on Social